JPWO2021076766A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021076766A5 JPWO2021076766A5 JP2022522603A JP2022522603A JPWO2021076766A5 JP WO2021076766 A5 JPWO2021076766 A5 JP WO2021076766A5 JP 2022522603 A JP2022522603 A JP 2022522603A JP 2022522603 A JP2022522603 A JP 2022522603A JP WO2021076766 A5 JPWO2021076766 A5 JP WO2021076766A5
- Authority
- JP
- Japan
- Prior art keywords
- demethoxycurcumin
- composition
- mammal
- use according
- octahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 21
- KTRRXJQAOOYSDA-UHFFFAOYSA-N 1,7-bis(4-hydroxyphenyl)heptane-3,5-dione Chemical compound C1=CC(O)=CC=C1CCC(=O)CC(=O)CCC1=CC=C(O)C=C1 KTRRXJQAOOYSDA-UHFFFAOYSA-N 0.000 claims description 20
- RSAHICAPUYTWHW-UHFFFAOYSA-N Hexahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 RSAHICAPUYTWHW-UHFFFAOYSA-N 0.000 claims description 20
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims description 20
- OELMAFBLFOKZJD-UHFFFAOYSA-N 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol Chemical compound C1=C(O)C(OC)=CC(CCC(O)CC(O)CCC=2C=C(OC)C(O)=CC=2)=C1 OELMAFBLFOKZJD-UHFFFAOYSA-N 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 12
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 12
- ZBFSUZGUYFFWGY-UHFFFAOYSA-N Platyphyllonol Natural products C=1C=C(O)C=CC=1CCC(=O)CC(O)CCC1=CC=C(O)C=C1 ZBFSUZGUYFFWGY-UHFFFAOYSA-N 0.000 claims description 10
- HJFYFYWETUVIHT-UHFFFAOYSA-N tetrahydrodemethoxycurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=CC(O)=CC=2)=C1 HJFYFYWETUVIHT-UHFFFAOYSA-N 0.000 claims description 10
- 235000005911 diet Nutrition 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 8
- 230000011759 adipose tissue development Effects 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 230000005976 liver dysfunction Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 2
- 108010082126 Alanine transaminase Proteins 0.000 claims description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 5
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915068P | 2019-10-15 | 2019-10-15 | |
| US62/915,068 | 2019-10-15 | ||
| PCT/US2020/055796 WO2021076766A1 (en) | 2019-10-15 | 2020-10-15 | Curcuminoid composition for therapeutic management of metabolic syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553173A JP2022553173A (ja) | 2022-12-22 |
| JPWO2021076766A5 true JPWO2021076766A5 (https=) | 2023-09-22 |
| JP2022553173A5 JP2022553173A5 (https=) | 2023-09-22 |
Family
ID=75382361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522603A Pending JP2022553173A (ja) | 2019-10-15 | 2020-10-15 | 代謝症候群の治療管理のためのクルクミノイド組成物 |
| JP2022522601A Pending JP2022551967A (ja) | 2019-10-15 | 2020-10-15 | クルクミノイド組成物および肺線維症の管理におけるその治療能力 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522601A Pending JP2022551967A (ja) | 2019-10-15 | 2020-10-15 | クルクミノイド組成物および肺線維症の管理におけるその治療能力 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11707438B2 (https=) |
| EP (2) | EP4045478B1 (https=) |
| JP (2) | JP2022553173A (https=) |
| CN (2) | CN114746102A (https=) |
| CA (2) | CA3153877C (https=) |
| WO (2) | WO2021076766A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230255969A1 (en) * | 2020-07-23 | 2023-08-17 | National University Of Singapore | Targeting immune pathologies induced by highly pathogenic coronaviruses |
| JP2023554640A (ja) * | 2020-12-17 | 2023-12-28 | サミ－サビンサ グループ リミテッド | 慢性炎症状態において終末糖化産物受容体（ｒａｇｅ）を標的とするための組成物 |
| WO2022203674A1 (en) * | 2021-03-25 | 2022-09-29 | Majeed, Muhammed | Compositions and methods for managing nephropathy |
| BR112023022756A2 (pt) * | 2021-04-30 | 2024-01-02 | Sami Sabinsa Group Ltd | Composições para gerenciamento de síndrome de ovário policístico |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0249747A (ja) | 1988-08-12 | 1990-02-20 | Kobe Steel Ltd | 抗酸化剤 |
| US6653327B2 (en) * | 1999-04-09 | 2003-11-25 | Sabinsa Corporation | Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays |
| JP2003002827A (ja) * | 2001-06-20 | 2003-01-08 | Kyowa Hakko Kogyo Co Ltd | 血中中性脂肪の増加の予防又は改善剤 |
| US6790979B2 (en) * | 2002-04-17 | 2004-09-14 | University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| US8784881B2 (en) * | 2004-03-05 | 2014-07-22 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
| US20060263309A1 (en) * | 2005-05-17 | 2006-11-23 | Bissett Donald L | Regulation of mammalian keratinous tissue using personal care compositions comprising tetrahydrocurcumin |
| US20080031980A1 (en) * | 2006-08-02 | 2008-02-07 | Al Rodriguez | Curcumin-containing composition, methods of making, and methods of using |
| US20080058426A1 (en) * | 2006-08-29 | 2008-03-06 | Muhammed Majeed | Composition and method for treating psoriasis |
| CN101255119B (zh) * | 2008-01-07 | 2014-05-21 | 沈阳药科大学 | 四氢姜黄素衍生物及盐类 |
| JP2012521412A (ja) * | 2009-03-23 | 2012-09-13 | ライラ ファーマシューティカルズ ピーブイティ．エルティディ． | 鼻のアレルギー疾患において適用するためのクルクミノイドおよびその代謝物 |
| CN101732292B (zh) * | 2010-01-25 | 2012-05-16 | 四川省中医药科学院 | 四氢姜黄素的用途 |
| CN102526004A (zh) * | 2010-01-25 | 2012-07-04 | 四川省中医药科学院 | 四氢姜黄素的新用途 |
| WO2011124573A1 (en) * | 2010-04-09 | 2011-10-13 | Unilever Plc | Oral care compositions |
| CN102078312A (zh) * | 2010-12-24 | 2011-06-01 | 中国药科大学 | 一种姜黄素类化合物干粉吸入剂及其制备方法和用途 |
| US9170257B2 (en) * | 2012-06-14 | 2015-10-27 | Signpath Pharma Inc. | Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin |
| US20150283093A1 (en) * | 2014-04-07 | 2015-10-08 | Muhammed Majeed | Nanoencapsulation of curcuminoid metabolites - process, composition and applications thereof |
| US9642886B2 (en) * | 2014-08-25 | 2017-05-09 | Srm University | Plant based formulation for the prevention and management of metabolic syndrome by its adiponectin enhancing property |
| DK3233068T3 (da) * | 2014-12-15 | 2021-09-13 | Aurea Biolabs Private Ltd | Fremgangsmåde til fremstilling af biotilgængelig hvid curcumin - en unik blanding af hydrogenerede curcuminoider |
| KR102876481B1 (ko) * | 2017-03-17 | 2025-10-27 | 케랄라 아유르베다 리미티드 (인디아) | 약초 조성물 |
| CN108771664B (zh) * | 2018-06-05 | 2020-09-08 | 中山大学 | 四氢姜黄素在改善过敏性哮喘的应用 |
| CN109833457A (zh) * | 2019-02-28 | 2019-06-04 | 孟凤仙 | 虎杖及姜黄及其活性物在治疗间质性肺病中的应用 |
| CN109674742A (zh) * | 2019-03-07 | 2019-04-26 | 康赋葆(深圳)生物医药科技有限公司 | 一种姜黄素类亲水凝胶骨架缓释组合物、制备方法及其在抗癌领域的应用 |
-
2020
- 2020-10-15 JP JP2022522603A patent/JP2022553173A/ja active Pending
- 2020-10-15 WO PCT/US2020/055796 patent/WO2021076766A1/en not_active Ceased
- 2020-10-15 EP EP20876349.0A patent/EP4045478B1/en active Active
- 2020-10-15 CN CN202080081641.8A patent/CN114746102A/zh active Pending
- 2020-10-15 CA CA3153877A patent/CA3153877C/en active Active
- 2020-10-15 US US17/071,637 patent/US11707438B2/en active Active
- 2020-10-15 EP EP20877123.8A patent/EP4045071B1/en active Active
- 2020-10-15 JP JP2022522601A patent/JP2022551967A/ja active Pending
- 2020-10-15 US US17/071,682 patent/US11491119B2/en active Active
- 2020-10-15 WO PCT/US2020/055802 patent/WO2021076771A1/en not_active Ceased
- 2020-10-15 CN CN202080079524.8A patent/CN114728876A/zh active Pending
- 2020-10-15 CA CA3153879A patent/CA3153879A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6673843B2 (en) | Curcumin and curcuminoid inhibition of angiogenesis | |
| Feng et al. | Mechanism of metabolic dysfunction-associated steatotic liver disease: Important role of lipid metabolism | |
| RU2016129266A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| Rhee et al. | Extract of Ginkgo biloba ameliorates streptozotocin-induced type 1 diabetes mellitus and high-fat diet-induced type 2 diabetes mellitus in mice | |
| Hong et al. | The aqueous extract from Artemisia capillaris Thunb. inhibits lipopolysaccharide-induced inflammatory response through preventing NF-κB activation in human hepatoma cell line and rat liver | |
| IL239893A (en) | Preparations including 15-ohepa and methods of use | |
| CN101897687B (zh) | 丙戊酸钠治疗肝脏炎症相关疾病的新用途 | |
| WO2020099926A1 (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| KIM et al. | Effect of dimethyl-4, 4'-dimethoxy-5, 6, 5', 6'-dimethylenedioxybiphenyl-2, 2'-dicarboxylate (DDB) on chemical-induced liver injury | |
| Kojima-Yuasa | Biological and pharmacological effects of polyphenolic compounds from Ecklonia cava | |
| JPWO2021076766A5 (https=) | ||
| Wal et al. | Role of natural compounds in non-alcoholic fatty liver diseases (NAFLD): a mechanistic approach | |
| Meng et al. | Taming fatty liver: can taurine combat metabolic dysfunction in MASLD? | |
| KR101685876B1 (ko) | 길경추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물 | |
| AU2003299772A1 (en) | Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity | |
| US20100160432A1 (en) | Curative drug for neurodegenerative diseases | |
| CN113648311B (zh) | 7-(2,2-二甲基-3-丁烯酰胺基)-八氢苯喹啉乙酸酯在制备降脂药物中的应用 | |
| CN111450102A (zh) | 一种促进非酒精性脂肪肝细胞脂质代谢药物的应用 | |
| CN108379272A (zh) | 猪去氧胆酸在制备减肥以及治疗或预防肥胖并发症药物中的应用 | |
| CHEN et al. | Beneficial effects of sanguisorbae radix in renal dysfunction caused by endotoxin in vivo | |
| Zarrin et al. | Persian Gulf brown seaweed extracts showing anti-obesity potency on adipogenic differentiation in human adipose-derived mesenchymal stem cells and obese male rats | |
| Singh et al. | Butyrate: a review on beneficial pharmacological and therapeutic effect | |
| US20130029996A1 (en) | Special composition for the use thereof as a drug | |
| EP1666035A1 (en) | Medicinal composition for treatment for fatty liver or liver disease | |
| CN111632060B (zh) | 一种含黄芩苷和二甲双胍的组合物及其制备方法与应用 |